Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 6/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.45 |
| ▸ | MAT2A | P31153 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3724931 | 1.00 | LMNA (0.50) | LMNACYP1A2CYP2D6MAPTFPR2 | |
| SCHEMBL3719762 | 0.92 | LMNA (0.52) | LMNACYP1A2CYP2D6MAPTFPR2 | |
| SCHEMBL3723034 | 0.86 | LMNA (0.51) | LMNACYP1A2CYP2D6MAPTFPR2 | |
| SCHEMBL13153800 | 0.86 | LMNA (0.48) | LMNACYP1A2CYP2D6MAPTFPR2 | |
| SCHEMBL1317468 | 0.83 | CYP1A2 (0.55) | LMNACYP1A2CYP2D6MAPTFPR2 | |
| SCHEMBL14743853 | 0.78 | FPR2 (0.56) | LMNAFPR2SCN9AMAT2AELANE | |
| SCHEMBL16023889 | 0.78 | FPR2 (0.56) | LMNAFPR2SCN9AMAT2AELANE | |
| SCHEMBL1319079 | 0.78 | MAPT (0.51) | LMNACYP1A2CYP2D6MAPTKMT2A | |
| SCHEMBL3205548 | 0.78 | MAPT (0.51) | LMNACYP1A2CYP2D6MAPTKMT2A | |
| SCHEMBL26604119 | 0.78 | CYP1A2 (0.52) | LMNACYP1A2CYP2D6MAPTFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010120854-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010120854-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | LMNA 4686/4885CYP1A2 1859/4885CYP2D6 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.